Related Experiment Videos
Proteomics--a new way for drug target discovery
S Müllner1, T Neumann, F Lottspeich
1Corporate Research and Technology, Hoechst Aktiengesellschaft, Frankfurt/Main, Germany.
Arzneimittel-Forschung
|April 2, 1998
Summary
Genomic data alone is insufficient for drug target discovery. Proteomics offers a powerful approach to link genes with protein function, advancing therapeutic development.
Area of Science:
- Genomics and Proteomics
- Drug Discovery and Development
Background:
- Genome projects generate vast data, challenging current drug target discovery strategies.
- DNA/RNA sequences alone are insufficient for identifying therapeutic targets due to the protein-centric nature of drug action.
- Gene expression levels do not always correlate directly with protein expression levels.
Purpose of the Study:
- To highlight the limitations of genomic data in drug discovery.
- To introduce proteomics as a key technology for linking genes to protein function.
- To emphasize the importance of protein-level analysis in developing new therapeutic concepts.
Main Methods:
- Analysis of genomic data, including DNA/RNA sequences.
- Subtractive expression pattern analysis.
- Emerging proteomics technologies for functional linkage.
Main Results:
- Genomic data presents challenges in handling, storage, and interpretation.
- Proteins, not DNA/RNA, are the primary sites of drug action.
- Proteomics is identified as a crucial technology for bridging the gap between genes and function.
Conclusions:
- Proteomics is essential for effective drug target discovery.
- Understanding protein function is critical for developing novel therapeutics.
- Integrating proteomics enhances the drug discovery and development pipeline.